Clinical Trial Update: Use of a Phosphodiesterase Type 5 Inhibitor to Improve Anabolic Resistance in Older Adults

View source ↗

Summary

A University of Arkansas-sponsored trial evaluating a phosphodiesterase type 5 inhibitor for improving anabolic resistance in older adults with sarcopenia has b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcopenia

Drugs mentioned

• PDE5 inhibitor (unspecified)

Snippet

Sponsor: University of Arkansas | Conditions: Sarcopenia | Status: WITHDRAWN